NG-350a is under clinical development by Akamis Bio and currently in Phase I for Squamous Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Squamous Non-Small Cell Lung Cancer have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NG-350a’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NG-350a is under development for the treatment of relapsed or refractory advanced metastatic epithelial tumors, ureter, bladder, urethra, head and neck cancer squamous cell carcinoma, squamous non-small cell lung cancer, non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma and metastatic pancreatic cancer. It is administered through intravenous and intratumoral routes. The therapeutic candidate is an antibody based oncolytic virus enadenotucirev (EnAd). It is developed based on the T-SIGn tumor specific delivery platform and AbEnAd technology. It acts by targeting B-Cell surface antigen CD40.
Akamis Bio overview
Akamis Bio, formerly PsiOxus Therapeutics Ltd, develops and discovers novel therapies for the treatment of cancer and other related diseases. The company utilizes T-SIGn, a tumor specific immuno gene platform to develop gene therapies for primary and metastatic solid tumors. Its platform has capabilities to be used in combination with CAR-T and other cell therapies to overcome poor immune cell infiltration, immunosuppressive properties of tumor microenvironment, and systematic toxicity issues. Akamis Bio’s product pipeline includes NG-350A and NG-641 to treat metastatic and advanced epithelial tumors. The company is also investigating NG-347, NG-348, and NG-796A drug programs for application in various cancer treatments. It has an operational presence in the US and the UK. Akamis Bio is headquartered in Abingdon, Oxfordshire, the UK.
For a complete picture of NG-350a’s drug-specific PTSR and LoA scores, buy the report here.